Calls for proposals
PRISM selects pilot paediatric clinical studies through a transparent, independent evaluation process, providing end-to-end support for multinational investigator-initiated research across Europe and Canada.
PRISM call for proposals on paediatric multinational investigator-initiated clinical studies
Paediatric Clinical Research Infrastructure Service Model (PRISM) is a European consortium aiming to strengthen the conduct of multinational paediatric research by providing infrastructure and expertise to investigator-initiated studies.
Funded by Horizon-Europe (GA101292607), PRISM selects, according to a two-stage procedure, pilot paediatric clinical studies to provide comprehensive, end-to-end support for multinational investigator-initiated studies conducted in 3 to 6 countries in Europe and Canada.
Short-listed projects get dedicated support from the PRISM consortium during the design and planning of the full application.
Following final assessment, selected projects receive funding covering the cost of investigation and trial coordination, and multinational trial management services provided by the PRISM consortium.
Key details
- Eligible studies: pragmatic, investigator-initiated randomised controlled trials comparing or optimising healthcare strategies (therapeutic, diagnostic or preventive interventions), and prospective observational cohort studies.
- Study population: birth to 18 years old. Any paediatric disease area except oncology and rare diseases.
- Recruitment: in 3 to 6 countries across Europe (EU, Norway, Switzerland, United Kingdom) and Canada, with a maximum of 15 sites (except cluster randomised controlled trials).
- Maximum study duration: 30 months, from study start-up to the close-out visit.
- Requested budget: 1–2 M€ for interventional studies, or up to 1 M€ for observational studies, including the mandatory ECRIN Coordinated Service Package.
- A single, non-commercial, experienced sponsor, with a sponsor representative where required.
Please read the call text and application guidelines in full before applying.
Questions: PRISM Joint Call Secretariat – call2026@prismeu.org
Watch the replay of the information webinar on YouTube.
Apply Full call text
Join the PRISM Independent Expert Evaluation Panel
Are you an experienced paediatrician, methodologist or clinical pharmacologist? PRISM is looking for experts to join its Independent Expert Evaluation Panel.
To ensure a transparent, high-quality and independent selection of the trials supported through its open calls, PRISM is establishing an Independent Expert Database. Reviewers will evaluate incoming proposals against the standard Horizon Europe criteria: Excellence, Impact, and Quality and efficiency of the implementation.
Please note that this call is not limited to the Stage 1 evaluation. The experts for Stage 2 (July to August 2027), which includes the evaluation of full study protocols, will also be selected from this same pool, and experts involved in Stage 1 may also be contacted for Stage 2.
Expert profiles
- Paediatric experts or sub-specialists with deep expertise within their clinical or scientific domain
- General paediatricians with a broad clinical and scientific perspective
- Methodologists, biostatisticians and clinical pharmacologists
Minimum qualifications
- Professional experience: at least 5 years of active clinical, methodological or research experience in paediatrics, pharmacology or clinical trial methodology.
- Track record: proven scientific experience (peer-reviewed publications, participation in international clinical trials, or network leadership).
- Language: professional fluency in written and spoken English.
- Independence: full impartiality and willingness to adhere to the Conflict of Interest (COI) guidelines.
Complete the brief online registration form (approximately 5 minutes) and attach your current CV.
Application deadline: 1 December 2026.
No calls have closed yet. PRISM's first call (TNA1) is open — past calls will be listed here once completed.
Frequently Asked Questions
The most asked questions about the PRISM TNA1 Call.
Do sites need to be defined at the Letter of Intent stage?
At the Letter of Intent stage, the sites must at least be identified.
Can PRISM fund a randomised controlled trial that has already started as a pilot study?
No. A randomised controlled trial that has already started as a pilot study is not eligible for support under this call. The same applies to a pilot study already running at one or two sites whose proposal expands its objectives and scales up to a larger number of sites: it remains ineligible. Applicants should therefore submit studies that have not yet started.
What is considered an eligible site?
An eligible site is a site that recruits participants. Hospitals can also be considered eligible sites.
Does the 30-month duration include study start-up?
The maximum study duration is 2.5 years (30 months), covering all phases from study start-up to completion of the close-out visit.
Who submits the application?
Only one submission is made per project, by the main Principal Investigator, on behalf of the whole consortium.
Discover PRISM
Learn more about the project, its objectives and the consortium behind the call.
About PRISM